en · de · es · fr · pt
melanotan-2-notes.peptides9000.com › Guide › Background And Receptor Mechanism — Evidence Review

Background And Receptor Mechanism — Evidence Review

By Editorial Desk · published 2026-01-12 · last reviewed 2026-02-18 · Guide

Heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalog of alpha-melanocyte-stimulating hormone
Primary receptor familyMelanocortin receptors MC1R through MC5RBinding is not subtype-selective
Development period1980sSynthesized during pigmentation and appetite research
Regulatory statusNot an approved medicineNo major regulator has authorized human use
Related compoundAfamelanotideLinear analog studied for photoprotection

Melanotan-2 Identity And Regulatory Status

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Related pages on this site

Reference notes

Regional treatment centres had also been set up, with large increases in the number of infected in the South Pyongan and South Hamgyong provinces. On 20 May, 168 confirmed cases of COVID-19 were reported, with cases of reported fever nearing 2 million, according to NK News. On 3 June, NK News reported that GAVI had received information that North Korea had started its vaccination rollout with Chinese vaccines, with an anonymous source telling Radio Free Asia that the first doses were being administered to soldiers working in the construction sector. From around June, vehicles had started reappearing in satellite imagery in Pyongyang, which suggested that the lockdown was at least being partially lifted in Pyongyang, with a source alleging that restrictions were relaxed to allow for a few hours of outdoor time every day from late May, though provincial cities appeared to be still locked down.

Executive Order 13985 of January 20, 2021 (Advancing Racial Equity and Support for Underserved Communities Through the Federal Government); Executive Order 13993 of January 20, 2021 (Revision of Civil Immigration Enforcement Policies and Priorities); Executive Order 14031 of May 28, 2021 (Advancing Equity, Justice, and Opportunity for Asian Americans, Native Hawaiians, and Pacific Islanders); Executive Order 14075 of June 15, 2022 (Advancing Equality for Lesbian, Gay, Bisexual, Transgender, Queer, and Intersex Individuals) among many others. Executive Order 14020 of March 8, 2021 (Establishment of the White House Gender Policy Council); Executive Order 13988 of January 20, 2021 (Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation). Executive Order 14020 was rescinded twice, once in this executive order and then again in Defending Women from Gender Ideology Extremism and Restoring Biological Truth to the Federal Government, passed the same day.

== Other species == Vernix was thought to be unique to human fetal development. In 2018, vernix-like material was reportedly obtained from pups of the California sea lion. Mass spectrometry of the material showed it to be fundamentally the same as human vernix, in both BCFA (branch-chain fatty acids) and squalene content. The presence of vernix throughout the infant gastro-intestinal tract, as well as in the meconium (first excretion), in both human and sea lion neonates, argues that the function of vernix may not be as an external skin protection, as often described in the literature, but as a preparation of the newborn GI tract against water-borne bacteria. As such, vernix caseosa, not present in any terrestrial mammal, including other primates, is one of several arguments for a possible semi-aquatic past of our ancestors.

=== Defining agrifood systems resilience === The resilience of agrifood systems builds on the concept of resilience, which originated in the study of ecosystems and evolved over 50 years into an object of study across an array of disciplines, including engineering, agriculture, economics and psychology. Although there is little agreement today as to a precise definition across disciplines, broadly speaking, resilience can be defined as the dynamic capacity to continue to achieve goals despite disturbances. In a call for cross-sectoral collaboration to prevent, anticipate, absorb, adapt and transform in the face of shocks and stresses across all sectors of society, the United Nations has developed and adopted the UN Common Guidance on Helping Build Resilient Societies. Since there is a wide variety of risks relating to understanding resilience, the UN offers the following definition: "the ability of individuals, households, communities, cities, institutions, systems and societies to prevent, anticipate, absorb, adapt, and transform positively, efficiently and effectively when faced with a wide range of risks, while maintaining an acceptable level of functioning and without compromising long-term prospects for sustainable development, peace and security, human rights and well-being for all." Resilience building is a system-wide multi-risk, multi-actor and multisectoral effort.

where dm/dt is the mass dissolution rate, D the diffusion coefficient, A the surface area of solid in contact with the dissolution medium, Cs the saturation solubility, C the bulk concentration, and h the thickness of the unstirred diffusion layer. Because A scales inversely with particle diameter, reducing median diameter from approximately 50 μm to 5 μm increases the available surface area roughly ten-fold and produces a corresponding increase in dissolution rate at constant solubility. At sub-micron diameters, Cs itself increases according to the Ostwald–Freundlich equation, providing an additional thermodynamic contribution to dissolution. Under the Biopharmaceutics Classification System (BCS), drugs are categorized by aqueous solubility and intestinal permeability. Micronization confers the greatest clinical benefit for BCS Class II compounds (low solubility, high permeability), where dissolution rate — not membrane permeation — limits absorption. For BCS Class III and IV compounds, in which permeability is the rate-limiting step, particle size reduction alone produces little change in bioavailability and must be combined with permeation enhancers or alternative delivery strategies.

Sources: en.wikipedia.org

Notes from published material

=== Regulation by keap1/nrf2/are pathway === External (via chemicals) and internal (stress response or caloric restriction) induction of NQO1 is mediated solely through the Keap1/Nrf2/ARE. Keap1 acts as the sensor which loses its ability to target Nrf2 for degradation upon exposure to the inducers. Nrf2 is consequently stabilized and accumulated in the nucleus upon which it binds to the AREs and initiates expression of cytoprotective genes including NQO1.

Meanwhile, Eric preemptively gets Harper fired from Pierpoint for forging her college transcripts, thereby protecting her from insider trading charges tied to her helping Jesse. Jesse does not appear in series 3, but is mentioned to be serving a 24-month prison sentence for tax evasion. At the end of series 3, Harper reads a news story reporting that Jesse has been released.

Research and public pressure have led to bans on the use of Bisphenol A in bottles and cups to be used by children. In 2008 Walmart announced that it would stop selling baby bottles and food containers containing BPA. As of 2017, these were applied in at least 40 countries. Canada classified BPA as "toxic" in 2008 under the Canadian Environmental Protection Act. In 2011 use of bisphenol A in baby bottles was forbidden in all EU countries, in China, in Malaysia, and South Africa. In July 2012, the FDA stated that BPA would no longer used in baby bottles and sippy cups, in response to a petition from the American Chemistry Council stating that this was now in line with industry practice. Other countries such as Argentina and Brazil followed suit by prohibiting bisphenol A in baby bottles. Korea has extended its BPA ban to include all children's utensils, containers and packaging as of January 2020. There are calls for increased regulation of BPA in India.

== Medical use and research == Epothilone D, with the generic drug name utidelone, was approved in China in 2021 for the treatment of metastatic breast cancer. Utidelone has shown benefits in a phase III breast cancer trial when added to capecitabine. One synthetic analog, ixabepilone, was approved in October 2007 by the United States Food and Drug Administration for use in the treatment of aggressive metastatic or locally advanced breast cancer that no longer responds to currently available chemotherapies. In November 2008, the EMEA refused a marketing authorization for ixabepilone. Epothilone B, with the generic drug name patupilone, was proven to contain potent in vivo anticancer activities at tolerated dose levels in several human xenograft models. As a result, patupilone and various analogs underwent various clinical phases. Patupilone and the fully synthetic sagopilone were tested in phase II trials and BMS-310705 was tested in phase I trials). Patupilone failed a phase III trial for ovarian cancer in 2010. Results of a phase III trial with ixabepilone (BMS-247550) in combination with capecitabine in metastatic breast cancer have been announced (2007 – leading to FDA approval).

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II an approved medication?

No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.

How does it differ from afamelanotide?

Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.

Why does receptor selectivity matter?

A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network